In summary, our results not only reveal a number of mechanistic insights related to CIGB-300 anti-neoplastic effect in AML cells, but also highlight the feasibility of protein kinase CK2 pharmacologic inhibition for AML-targeted therapy. The gene discussed is CSNK2A1; the disease is acute myeloid leukemia.